Cancer is a leading cause of mortality and morbidity worldwide. Despite major
improvements in current therapeutic methods, ideal therapeutic strategies for improved …

It is well known that cancer cells are heterogeneous in nature and very distinct from their
normal counterparts. Commonly these cancer cells possess different and complementary …

We improve the potency of antibody–drug conjugates (ADCs) containing the human
epidermal growth factor receptor 2 (HER2)-specific antibody pertuzumab by substantially …

An efficient and attractive platform for synthesizing phosphatidylserine is indispensable for
driving large-scale industrial applications. Given the interfacial effect of phospholipase D …

Current treatments for antibody-mediated autoimmunity are associated with lack of
specificity, leading to immunosuppressive effects. To overcome this limitation, we have …

Glioblastoma multiforme is the most common primary intracranial malignancy, but its
etiology and pathogenesis are still unclear. With the deepening of human genome research …

Phospholipid scramblases (PLSCRs) that catalyze rapid mixing of plasma membrane lipids
result in surface exposure of phosphatidyl serine (PS), a lipid normally residing to the inner …

Current treatment regimens in cancer cases cause significant side effects and cannot
effectively eradicate the advanced disease. Hence, much effort has been expended over the …

Structures can now be predicted for any protein using programs like AlphaFold and Rosetta,
which rely on a foundation of experimentally determined structures of architecturally diverse …

Protein–drug conjugates are emerging tools to combat cancers. Here, we adopted an
indirect thiolation‐and‐conjugation method as a general strategy to prepare protein–drug …